Hualan Biological Engineering Inc.
002007
Rang in aandelen
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Aandeelprijs
$1.92
Marktkapitalisatie
$3.50B
Verandering (1 dag)
-1.39%
Verandering (1 jaar)
-19.45%
Land
CN
Handel Hualan Biological Engineering Inc. (002007)
Categorie
Healthcare
P/B-ratio voor Hualan Biological Engineering Inc. (002007)
P/B-ratio op October 2026 TTM: 2.13
Volgens de meest recente financiële rapporten en aandelenkoers van Hualan Biological Engineering Inc. is de huidige P/B-ratio (TTM) 2.13. Eind 2024 had het bedrijf een P/B-ratio van 2.59.
P/B-ratiohistoriek voor Hualan Biological Engineering Inc. van 2001 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 2.13 | -11.18% |
| 2025 | 2.40 | -7.39% |
| 2024 | 2.59 | -27.01% |
| 2023 | 3.55 | -10.48% |
| 2022 | 3.97 | -37.62% |
| 2021 | 6.36 | -37.60% |
| 2020 | 10.20 | 35.87% |
| 2019 | 7.51 | 49.25% |
| 2018 | 5.03 | -10.18% |
| 2017 | 5.60 | -28.94% |
| 2016 | 7.88 | 12.72% |
| 2015 | 6.99 | 22.97% |
| 2014 | 5.69 | 5.58% |
| 2013 | 5.38 | 15.44% |
| 2012 | 4.66 | -23.42% |
| 2011 | 6.09 | -52.62% |
| 2010 | 12.85 | 7.25% |
| 2009 | 11.99 | 55.58% |
| 2008 | 7.70 | -57.54% |
| 2007 | 18.15 | 186.87% |
| 2006 | 6.33 | 322.88% |
| 2005 | 1.50 | 22.78% |
| 2004 | 1.22 | -75.16% |
| 2003 | 4.90 | -27.47% |
| 2002 | 6.76 | -30.90% |
| 2001 | 9.79 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 193.25% |
US
|
|
| 13.2547 | 521.82% |
US
|
|
| 4.4521 | 108.86% |
AU
|
|
| 6.3632 | 198.52% |
NL
|
|
| 3.2932 | 54.49% |
BE
|
